Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.

Autor:	Ren P; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Cao Z; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Mo R; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Liu Y; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Chen L; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Li Z; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Zhou T; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Lu J; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Liu Y; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Guo Q; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Chen R; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Zhou H; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Xiang X; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Cai W; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Wang H; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Bao S; b Discipline of Pathology , the University of Sydney , Sydney , NSW , Australia., Xu Y; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Gui H; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China., Xie Q; a Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China.
Jazyk:	angličtina
Zdroj:	Expert opinion on biological therapy [Expert Opin Biol Ther] 2018 Oct; Vol. 18 (10), pp. 1085-1094. Date of Electronic Publication: 2018 Sep 13.
DOI:	10.1080/14712598.2018.1518423
Abstrakt:	Background: The effect of nucleos(t)ide analogs (NAs) versus interferon (IFN) on the occurrence of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) is controversial. We assessed whether antiviral strategy affected HCC development in CHB patients at different HCC risks. Methods: 1112 CHB patients with antiviral therapy were included in this retrospective study. Patients treated with NAs only were classified into NAs group (n = 682) while those received IFN treatment with or without NAs were defined as IFN group (n = 430). Propensity score matching (PSM) was applied to minimize baseline differences. Results: Totally, 31 patients developed HCC during follow-up (median 5.41 years). The cumulative HCC incidence at 10 years was significantly lower in the IFN group than NAs group (2.7% vs 8.0%, p < 0.001). Similar results were obtained in the PSM-cohort. Patients with IFN-based treatment were less likely to develop HCC than those with NAs (Hazard ratio = 0.15; 95% CI 0.04-0.66; p = 0.012). Subgroup analyses demonstrated that this superiority of IFN in reducing HCC development was obvious in patients at high- but not low-risk of HCC. Conclusions: Reduction of HCC development was more significant in CHB patients at higher HCC risk with IFN-based therapy than NAs treatment.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu